Recent Updates
Recently added Catalysts
OCS Neutral Sentiment

Oculis Publishes 2025 Consolidated Financial Statements

Thursday, March 5, 2026 BiopharmaWatch Research 1 min read
Add on Google
Key Takeaway: Oculis has published its audited consolidated financial statements for the year 2025, along with the Management Discussion and Analysis (MD&A). These documents have been filed with the SEC using form 20-F. The announcement follows a previous press release on March 3, 2026. Additional attachments, including the financial statements and ESEF reporting, are included in the release.
Price reaction · baseline $27.72 (2026-03-04 close) · hit after-hours · 2 other OCS headline(s) in the window, move may be shared
day 0 close
+0.1%

Market Sentiment Analysis

BiopharmaWatch Analysis

From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+32%
120-day peak, hindsight
Typical move
3.8%
average across 4 past catalysts
Lead asset
Privosegtor
Phase 3 · Optic Neuritis

Full Press Release Details

ZUG, Switzerland, March 05, 2026 (GLOBE NEWSWIRE) -- Following the Company‘s press release published on March 3, the audited consolidated financial statements for the financial year 2025 and the MD&A, which have now been filed with the SEC on form 20-F, are attached.
Oculis 2025 Consolidated IFRS Financial Statements
Oculis ESEF reporting

Frequently Asked Questions

What financial statements were filed by Oculis?

Oculis filed its audited consolidated financial statements for 2025.

When was the press release regarding financial statements issued?

The press release was published on March 3, 2026.

In which format were Oculis's financial statements filed?

The financial statements were filed on form 20-F with the SEC.

What type of reporting is included in the Oculis filing?

The filing includes ESEF reporting for Oculis.

ShareAdd on Google
Tags: OCS Viatris Investor Conferences Healthcare Oculis 2025 financials SEC filing Zug Switzerland consolidated statements
Last updated: Mar 5, 2026

Biotech snapshot

Lead asset
PrivosegtorPhase 3
Optic Neuritis →

Catalyst track record

+32%
best trade around OCS's most recent catalyst

Peak hindsight return over a 120-day window, across 4 tracked FDA/PDUFA catalysts for OCS.

See every catalyst's timing & PoA →